Not logged in Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
From electrons to phase diagrams with machine learning potentials using pyiron based automated workflows Menon, Sarath; Lysogorskiy, Yury; Knoll, Alexander L. M.; Leimeroth, Niklas; Poul, Marvin; Qamar, Minaam; Janssen, Jan; Mrovec, Matous; Rohrer, Jochen; Albe, Karsten; Behler, Joerg; Drautz, Ralf; Neugebauer, Joerg Share Save
Share Save
Share Save
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study Woeckel, A.; Brucker, C.; Decker, T.; Fasching, P.; Goehler, T.; Jackisch, C.; Janssen, J.; Koehler, A.; Luedtke-Heckenkamp, K.; Lueftner, D.; Van Mackelenbergh, M.; Marme, F.; Nusch, A.; Rautenberg, B.; Reimer, T.; Weide, R.; Wimberger, P.; Figueroa, S. Maslanka; Roos, C.; Schmidt, M. Share Save
Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) plus endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)) Decker, T.; Brucker, C.; Fasching, P.; Goehler, T.; Jackisch, C.; Janssen, J.; Koehler, A.; Luedtke-Heckenkamp, K.; Luetner, D.; Van Mackelenbergh, M.; Marme, F.; Nusch, A.; Rautenberg, B.; Reimer, T.; Schmidt, M.; Weide, R.; Wimberger, P.; Figueroa, S. Maslanka; Roos, C.; Woeckel, A. Share Save
Therapy management and safety of 1st-line ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)) Marme, F.; Brucker, C.; Decker, T.; Fasching, P.; Goehler, T.; Jackisch, C.; Janssen, J.; Koehler, A.; Luedtke-Heckenkamp, K.; Lueftner, D.; Van Mackelenbergh, M.; Nusch, A.; Rautenberg, B.; Schmidt, M.; Reimer, T.; Weide, R.; Wimberger, P.; Figueroa, S. Maslanka; Roos, C.; Woeckel, A. Share Save
Share Save
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study Dechow, Tobias; Riera-Knorrenschild, Jorge; Hackanson, Bjorn; Janssen, Jan; Schulz, Holger; Oppermann, Ursula; Chiabudini, Marco; von Weikersthal, Ludwig Fischer; Budweiser, Stephan; Nacke, Axel; Taeuscher, Dagmar; Welslau, Manfred; Potthoff, Karin Share Save
RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib plus endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2-ABC Jackisch, Christian; Brucker, Cosima; Decker, Thomas; Engel, Anne; Fasching, Peter A.; Gohler, Thomas; Janssen, Jan; Kohler, Andreas; Ludtke-Heckenkamp, Kerstin; Luftner, Diana; van Mackelenbergh, Marion; Marme, Frederik; Nusch, Arnd; Rautenberg, Beate; Reimer, Toralf; Schmidt, Marcus; Weide, Rudolf; Wimberger, Pauline; Roos, Christian; Wockel, Achim Share Save
Progression-free survival and patient-reported outcomes in HR+, HER2-ABC patients treated with first-line ribociclib plus endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA Fasching, Peter A.; Brucker, Cosima; Decker, Thomas; Engel, Anne; Gohler, Thomas; Jackisch, Christian; Janssen, Jan; Kohler, Andreas; Ludtke-Heckenkamp, Kerstin; Luftner, Diana; van Mackelenbergh, Marion; Marme, Frederik; Nusch, Arnd; Rautenberg, Beate; Reimer, Toralf; Schmidt, Marcus; Weide, Rudolf; Wimberger, Pauline; Roos, Christian; Wockel, Achim Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
